Literature DB >> 34162473

Poster Exhibit 2: Non-prostate Genitourinary Cancers.

.   

Abstract

Entities:  

Year:  2021        PMID： 34162473      PMCID： PMC8232938          DOI： 10.5489/cuaj.7401

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  9 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

2.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

3.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Nizar M Tannir; Paul N Mainwaring; Brian I Rini; Hans J Hammers; Frede Donskov; Bruce J Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y C Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N Sternberg; David F McDermott; Dana T Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E Hutson; Sumanta Pal; Robert J Motzer
Journal:  Lancet Oncol       Date:  2016-06-05       Impact factor: 41.316

4.  Kidney Biopsy Adequacy: A Metric-based Study.

Authors:  German Ferrer; Nicole K Andeen; Joseph Lockridge; Douglas Norman; Bryan R Foster; Donald C Houghton; Megan L Troxell
Journal:  Am J Surg Pathol       Date:  2019-01       Impact factor: 6.394

5.  Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-a Prospective Double-Blind Clinical Study.

Authors:  Paramananthan Mariappan; Victoria Lavin; Chu Qin Phua; Shahid Aziz Anwar Khan; Roland Donat; Gordon Smith
Journal:  Urology       Date:  2017-08-14       Impact factor: 2.649

6.  Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.

Authors:  Lester D R Thompson
Journal:  Am J Surg Pathol       Date:  2002-05       Impact factor: 6.394

7.  Prediction of histological stage based on cystoscopic appearances of newly diagnosed bladder tumours.

Authors:  V A During; G M Sole; A K Jha; J A Anderson; R T Bryan
Journal:  Ann R Coll Surg Engl       Date:  2016-08-09       Impact factor: 1.891

Review 8.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.

Authors:  Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan
Journal:  J Urol       Date:  2016-06-16       Impact factor: 7.450

9.  Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy.

Authors:  Daniel A Orringer; Balaji Pandian; Yashar S Niknafs; Todd C Hollon; Julianne Boyle; Spencer Lewis; Mia Garrard; Shawn L Hervey-Jumper; Hugh J L Garton; Cormac O Maher; Jason A Heth; Oren Sagher; D Andrew Wilkinson; Matija Snuderl; Sriram Venneti; Shakti H Ramkissoon; Kathryn A McFadden; Amanda Fisher-Hubbard; Andrew P Lieberman; Timothy D Johnson; X Sunney Xie; Jay K Trautman; Christian W Freudiger; Sandra Camelo-Piragua
Journal:  Nat Biomed Eng       Date:  2017-02-06       Impact factor: 25.671
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.